TY - JOUR
T1 - Treatment effect of alirocumab according to age group, smoking status, and hypertension
T2 - Pooled analysis from 10 randomized ODYSSEY studies
AU - Raal, Frederick J.
AU - Tuomilehto, Jaakko
AU - Sposito, Andrei C.
AU - Fonseca, Francisco A.
AU - Averna, Maurizio
AU - Farnier, Michel
AU - Santos, Raul D.
AU - Ferdinand, Keith C.
AU - Wright, R. Scott
AU - Navarese, Eliano Pio
AU - Lerch, Danielle M.
AU - Louie, Michael J.
AU - Lee, L. Veronica
AU - Letierce, Alexia
AU - Robinson, Jennifer G.
N1 - Publisher Copyright:
© 2019 National Lipid Association
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Background: Age, smoking, hypercholesterolemia, and hypertension are major risk factors for atherosclerotic cardiovascular disease. Objective: We examined whether the effects of alirocumab on low-density lipoprotein cholesterol (LDL-C) differed according to age, hypertension, or smoking status. Methods: Data were pooled from 10 Phase 3 ODYSSEY randomized trials (24–104 weeks’ duration) in 4983 people with heterozygous familial hypercholesterolemia (FH) or non–familial hypercholesterolemia (3188 on alirocumab, 1795 on control [620 on ezetimibe and 1175 on placebo]). Most participants received concomitant maximum tolerated statin therapy. In 8 trials, the alirocumab dose was increased from 75 mg every 2 weeks (Q2W) to 150 mg Q2W at Week 12 if predefined risk-based LDL-C goals were not achieved at Week 8 (≥70 mg/dL in very high cardiovascular risk; ≥100 mg/dL in moderate or high cardiovascular risk). Two trials compared alirocumab 150 mg Q2W vs placebo. The efficacy and safety of alirocumab were assessed post hoc in subgroups stratified by age (<65, ≥65 to <75, ≥75 years) and baseline hypertension or smoking status. Results: Alirocumab reduced LDL-C by 23.7% (75/150 mg vs ezetimibe + statin) to 65.4% (150 mg vs placebo + statin) from baseline to Week 24 vs control. Subgroup analyses confirmed no significant interactions in response to alirocumab between age group, hypertension, or smoking status. Overall rates of treatment-emergent adverse events were similar between alirocumab and control groups. Conclusions: In this pooled analysis from 10 trials, alirocumab led to substantial LDL-C reductions vs control in every age group and regardless of hypertension or smoking status. Alirocumab was well tolerated in all subgroups.
AB - Background: Age, smoking, hypercholesterolemia, and hypertension are major risk factors for atherosclerotic cardiovascular disease. Objective: We examined whether the effects of alirocumab on low-density lipoprotein cholesterol (LDL-C) differed according to age, hypertension, or smoking status. Methods: Data were pooled from 10 Phase 3 ODYSSEY randomized trials (24–104 weeks’ duration) in 4983 people with heterozygous familial hypercholesterolemia (FH) or non–familial hypercholesterolemia (3188 on alirocumab, 1795 on control [620 on ezetimibe and 1175 on placebo]). Most participants received concomitant maximum tolerated statin therapy. In 8 trials, the alirocumab dose was increased from 75 mg every 2 weeks (Q2W) to 150 mg Q2W at Week 12 if predefined risk-based LDL-C goals were not achieved at Week 8 (≥70 mg/dL in very high cardiovascular risk; ≥100 mg/dL in moderate or high cardiovascular risk). Two trials compared alirocumab 150 mg Q2W vs placebo. The efficacy and safety of alirocumab were assessed post hoc in subgroups stratified by age (<65, ≥65 to <75, ≥75 years) and baseline hypertension or smoking status. Results: Alirocumab reduced LDL-C by 23.7% (75/150 mg vs ezetimibe + statin) to 65.4% (150 mg vs placebo + statin) from baseline to Week 24 vs control. Subgroup analyses confirmed no significant interactions in response to alirocumab between age group, hypertension, or smoking status. Overall rates of treatment-emergent adverse events were similar between alirocumab and control groups. Conclusions: In this pooled analysis from 10 trials, alirocumab led to substantial LDL-C reductions vs control in every age group and regardless of hypertension or smoking status. Alirocumab was well tolerated in all subgroups.
KW - Age
KW - Cholesterol
KW - Hypercholesterolemia
KW - Hypertension
KW - PCSK9
KW - Smoking
UR - http://www.scopus.com/inward/record.url?scp=85069927449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069927449&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2019.06.006
DO - 10.1016/j.jacl.2019.06.006
M3 - Article
C2 - 31377052
AN - SCOPUS:85069927449
SN - 1933-2874
VL - 13
SP - 735
EP - 743
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 5
ER -